In an interview with VEJA, prominent physician Dr. Fabiano M. Serfaty has described peptides as one of the most exciting frontiers in modern medicine, calling them “the new gold rush” for researchers and clinicians. In a recent column, Serfaty underscored both the promise and the risks of these molecules, which act as biological messengers capable of regulating cellular and metabolic functions.
Promise and Proven Success
Peptides are short chains of amino acids, naturally present in the body or synthesized for specific biological effects. Some have already transformed medical practice. “Examples like insulin and GLP‑1 receptor agonists have revolutionized treatment for diabetes and obesity,” Serfaty noted, pointing to decades of clinical evidence supporting their safety and efficacy.
These successes have fueled intense scientific and commercial interest. The physician emphasized that peptides are not a single drug but a broad class of molecules with enormous therapeutic potential.
Hype Versus Evidence
Serfaty cautioned that the surge in wellness marketing has blurred the line between proven therapies and experimental compounds. “The market has grown quickly, and with that growth comes a responsibility to be clear about what is being sold and how it is handled,” he said.
Many peptides promoted online — such as BPC‑157, TB‑500, and Epitalon — show intriguing results in laboratory or animal studies but lack robust clinical trials in humans. Serfaty warned that regulatory decisions should not be confused with scientific validation: “A molecule can seem extremely promising in the lab and still fail to show benefit in people, or even cause unexpected adverse effects.”
Regulatory and Ethical Concerns
The physician highlighted recent regulatory debates in the United States, where some peptides were recommended for compounding pharmacy use. He stressed that such moves do not equate to approval as medicines. “In medicine based on evidence, a therapy should only be incorporated when well‑conducted studies consistently demonstrate efficacy and safety,” Serfaty explained.
He also underscored the ethical duty of doctors to distinguish between innovation and experimentation. Patients, he argued, deserve transparency about whether a therapy is established or still investigational.
For Serfaty, peptides represent both a revolution and a bubble: proven molecules like GLP‑1 agonists are reshaping care, while others remain speculative. His message to the public is clear: “Innovation must always be validated by science before being incorporated into clinical practice. Extraordinary promises require extraordinary evidence.”